Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E1.95 EPS (ttm)1.94 Insider Own0.02% Shs Outstand2.45M Perf Week7.06%
Market Cap9.29M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.45M Perf Month-38.47%
Income0.29M PEG- EPS next Q- Inst Own0.30% Short Float1.13% Perf Quarter-40.50%
Sales3.32M P/S2.80 EPS this Y- Inst Trans- Short Ratio0.02 Perf Half Y-10.63%
Book/sh14.46 P/B0.26 EPS next Y- ROA2.36% Short Interest0.03M Perf Year-84.81%
Cash/sh0.87 P/C4.38 EPS next 5Y- ROE8.05% 52W Range2.80 - 27.56 Perf YTD-22.34%
Dividend Est.- P/FCF- EPS past 5Y-62.50% ROI7.01% 52W High-86.25% Beta1.40
Dividend TTM- Quick Ratio0.96 Sales past 5Y0.00% Gross Margin47.12% 52W Low35.36% ATR (14)0.65
Dividend Ex-Date- Current Ratio1.17 EPS Y/Y TTM102.65% Oper. Margin-194.06% RSI (14)46.82 Volatility24.17% 15.39%
Employees3 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin8.65% Recom1.00 Target Price520.00
Option/ShortNo / No LT Debt/Eq0.00 EPS Q/Q- Payout- Rel Volume0.26 Prev Close3.86
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume1.32M Price3.79
SMA20-2.71% SMA50-14.37% SMA200-52.72% Trades Volume337,363 Change-1.81%
Feb-20-24 07:14AM
Jan-29-24 07:18AM
Jan-24-24 01:49PM
09:28AM Loading…
Jan-19-24 09:28AM
Jan-04-24 07:18AM
Dec-13-23 02:02PM
Dec-07-23 09:05AM
Dec-05-23 08:47AM
Dec-01-23 08:14AM
Nov-28-23 08:55AM
08:41AM Loading…
Nov-27-23 08:41AM
Nov-24-23 08:55AM
Nov-22-23 09:49AM
Nov-15-23 10:55AM
Nov-10-23 09:10AM
Oct-31-23 11:08AM
Oct-24-23 07:20AM
Oct-17-23 08:00AM
Oct-16-23 09:45AM
Oct-13-23 04:28PM
Oct-11-23 09:15AM
07:33AM Loading…
Oct-03-23 07:33AM
Sep-29-23 07:45AM
Sep-27-23 07:58AM
Sep-20-23 06:30AM
Sep-12-23 09:15AM
Sep-07-23 09:15AM
Aug-15-23 09:50AM
Aug-14-23 12:20PM
Aug-10-23 09:10AM
Aug-09-23 04:40PM
Aug-01-23 10:30AM
Jul-14-23 07:55AM
Jun-30-23 09:25AM
Jun-21-23 10:30AM
Jun-16-23 09:05AM
Jun-07-23 08:05AM
Jun-02-23 09:00AM
May-30-23 08:40AM
May-08-23 06:35AM
May-02-23 07:25AM
Apr-21-23 08:30AM
Apr-04-23 08:15AM
Mar-28-23 09:00AM
Mar-10-23 04:15PM
Mar-09-23 07:30AM
Mar-06-23 07:45AM
Feb-27-23 09:11AM
Feb-23-23 08:45AM
Feb-22-23 08:00AM
Feb-17-23 08:00AM
Feb-15-23 08:30AM
Jan-25-23 08:30AM
Jan-23-23 02:15PM
Jan-18-23 07:30AM
Jan-17-23 08:30AM
Jan-09-23 08:30AM
Jan-05-23 09:00AM
Dec-14-22 09:15AM
Dec-07-22 08:40AM
Nov-29-22 08:00AM
Nov-15-22 10:25AM
Nov-08-22 07:00AM
Nov-07-22 08:45AM
Nov-01-22 08:30AM
Oct-28-22 07:45AM
Oct-12-22 09:00AM
Sep-30-22 07:00AM
Sep-22-22 08:30AM
Sep-14-22 07:35AM
Aug-24-22 07:30AM
Aug-19-22 06:45AM
Aug-18-22 08:15AM
Aug-15-22 08:30AM
Aug-12-22 08:00AM
Aug-08-22 08:55AM
Aug-01-22 09:30AM
Jul-21-22 07:22AM
SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.